

Application Number 09/403,627
Filing Date: May 31, 2000
Docket 759-11
Page 29 of 30

REMARKS

By this amendment, Applicant(s) have undertaken to cancel claims 1-20 and add new claims 21-103.

Support for new claims 21-103 as follows:

- ☒ New claims 21-28 recite compositions of peptide analogues and are supported by the specification as filed and original claims 1-4 (to uses of these peptides).
- ☒ New claim 29-34 recite peptide analogue compositions and are supported by the specification as filed and the original claim 5.
- ☒ New claims 35-38 recite peptide analogue compositions and are supported by the specification as filed and the original claim 6.
- ☒ New claims 39-48 recite the MART1 peptide analogue compositions and are supported by the specification as filed and the original claim 7.
- ☒ New claims 49-55 recite the influenza virus peptide analogue compositions and are supported by the specification as filed and the original claim 8.
- ☒ New claims 56-57 recite the HIV1/AIDS virus peptide analogue compositions and are supported by the specification as filed and the original claim 9.
- ☒ New claims 58-60 recite the HIV1/AIDS peptide analogue compositions and are supported by the specification as filed and the original claim 9.
- ☒ New claims 61-63 recite new methods of treatment with peptide analogue compositions and are supported by the specification as filed and the original claim 10.
- ☒ New claim 64 recites a method of treating/preventing a pathological condition with a peptide analogue and is supported by the specification as filed.
- ☒ New claims 65-68 recite the pharmaceutical compositions and are supported by the specification as filed and the original claim 11.
- ☒ New claims 69-77 recite the peptide vaccines and are supported by the specification as filed and the original claim 12.
- ☒ New claims 78-79 recite the diagnostic compositions and are supported by the specification as filed and the original claim 13.

Application Number 09/403,627
Filing Date: May 31, 2000
Docket 759-11
Page 30 of 30

IX P New claims 80-83 recite peptide analogue complexes and are supported by the specification as

filed and the original claim 14.

X P New claims 84-85 recite *in vitro* diagnosis using the peptide analogue compositions and are supported by the specification as filed and the original claim 15.

XI P New claims 86-89 recite kits for the diagnostic methods and are supported by the specification as filed and the original claim 16.

XII P New claims 90-92 recite antibodies against peptide analogue complexes and are supported by the specification as filed and the original claim 17.

New claim 93 relates to pharmaceutical composition containing antibodies against peptide analogue complexes and are supported by the specification as filed and the original claim 18.

XIII P New claims 94-98 recite a process for screening peptide analogue compositions and are supported by the specification as filed and the original claim 19.

New claims 99-103 recite a kit for screening peptide analogue compositions and are supported by the specification as filed and the original claim 20.

No new matter has been added by this amendment. If the Examiner has any questions or comments relating to the present application, the Examiner is invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,

Algis Anilionis
Algis Anilionis, Ph.D.
Registration No.: 36,995
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
AA/jb